In general, any nonhuman antibody that has been engineered to have human immunoglobulin domains substituted for all regions except the antigen-binding site. In practice, usually a modified mouse monoclonal antibody directed against a therapeutically important target (e.g. infliximab directed against TNFα). The objective is to make the antibody minimally antigenic so that repeated treatment is possible.
Subjects: Medicine and Health — Chemistry.